Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.67M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 1.84M

Average 1.44M

Income Statement

Follow revenue through to earnings.

Revenue

$884,000.00

FY 2025 · Annual

-39.2% YoY

Operating Income

-$113.56M

FY 2025 · Annual

Net Income

-$103.12M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Jun 2022
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue10.8M7.1M1.43M1.45M884K
Cost of Revenue6.18M5.47M000
Gross Profit4.62M1.63M1.43M(852K)(2.37M)
Gross Margin42.8%23.0%100.0%-58.6%-267.8%
Research & Development2.58M2.6M21.31M41.64M84.22M
Selling, General & Admin9.43M14.21M21.06M26.61M30.23M
Operating Expenses12.01M17.43M42.38M92.34M113.56M
Depreciation & Amortization248K344K981K2.31M3.25M
EBITDA(7.39M)(14.84M)(39.96M)10.46M(100.8M)
EBITDA Margin-68.5%-208.9%-2786.6%719.3%-11402.8%
Operating Income(7.39M)(15.18M)(40.94M)10.46M(113.56M)
Operating Margin-68.5%-213.7%-2855.0%719.3%-12846.6%
Interest Income119K1.12M934K10.52M8.11M
Interest Expense119K084K(48K)376K
Other Income / Expenses119K512K835K(91.84M)9.14M
Income Before Tax(7.27M)(14.67M)(40.11M)(81.38M)(104.43M)
Pre-Tax Margin-67.4%-206.5%-2796.8%-5596.7%-11813.1%
Income Tax Expense(119K)0(2.65M)(2.1M)(793K)
Net Income(7.15M)(14.67M)(46.51M)(79.28M)(103.12M)
Net Margin-66.3%-206.5%-3243.2%-5452.5%-11665.3%
EPS (Basic)(0.13)(0.27)(0.85)(1.23)(1.40)
EPS (Diluted)(0.13)(0.27)(0.85)(1.23)(1.40)
Weighted Avg Shares54.91M54.91M54.91M64.43M73.81M
Weighted Avg Shares (Diluted)54.91M54.91M54.91M64.43M73.81M

CATX Earnings Waterfall · TTM

AMEX:CATX · Revenue to Net Income

Key Ratios

EPS$-26.44
Gross Margin-1014.1%
Net Margin-35369.8%
P/E Ratio-1.7
P/S Ratio1708.8

Analysis

$618.0K of revenue converted into -$111.1M of net income for the selected period. Gross margin is -1014.1% and net margin is -35369.8%, showing how much revenue survives after costs and taxes. EPS is $-26.44, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
SC 13D/ASC 13D/A filingNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 9, 2026

How much revenue does CATX generate?

Perspective Therapeutics, Inc. (CATX) reported $884,000.00 of revenue in fiscal 2025.

Is CATX profitable?

Perspective Therapeutics, Inc. (CATX) reported -$103.12M of net income, with a net margin of -11665.3%.